A case with relapsed transient neonatal diabetes mellitus treated with sulfonylurea, ending chronic insulin requirement

• Published in: Endocrinology, diabetes & metabolism case reports Vol. 2018; no. 1; pp. 1 - 4
• Main Authors: Ando, Akihiko, Nagasaka, Shoichiro, Ishibashi, Shun
• Format: Journal Article
• Language: English
• Published: England Bioscientifica Ltd 11.04.2018; Bioscientifica
• Subjects: Adult; C-peptide (24-hour urine); C-peptide (blood); Fatigue; Female; GADA; Genetics; Gliclazide; Glucagon; Glucose (blood, fasting); Glucose tolerance (oral); Haemoglobin A1c; Hyperglycaemia; Insulin; Insulin Aspart; Insulin lispro; Japan; Molecular genetic analysis; Neonatal diabetes; Polydipsia; Sulphonylureas; Unusual Effects of Medical Treatment; Urinalysis; White; C-peptide (24-hour urine); Hyperglycaemia; Urinalysis; Glucagon; Insulin lispro; Sulphonylureas; Adult; Female; C-peptide (blood); Genetics; Neonatal diabetes; Polydipsia; Unusual effects of medical treatment; Glucose tolerance (oral); Glucose (blood, fasting); Japan; Haemoglobin A1c; Fatigue; Insulin; April; 2018; White; Molecular genetic analysis; Insulin Aspart; GADA; Gliclazide
• ISSN: 2052-0573; 2052-0573
• DOI: 10.1530/EDM-18-0005

Summary We report a case of a woman with diabetes mellitus caused by a genetic defect in ABCC8-coding sulfonylurea receptor 1 (SUR1), a subunit of the ATP-sensitive potassium (KATP) channel protein. She was diagnosed with diabetes at 7 days after birth. After intravenous insulin drip for 1 month, her hyperglycaemia remitted. At the age of 13 years, her diabetes relapsed, and after that she had been treated by intensive insulin therapy for 25 years with relatively poor glycaemic control. She was switched to oral sulfonylurea therapy and attained euglycaemia. In addition, her insulin secretory capacity was ameliorated gradually. Learning points: Genetic testing should be considered in any individuals or family with diabetes that occurred within the first year or so of life. Sulfonylurea can achieve good glycaemic control in patients with KATP channel mutations by restoring endogenous insulin secretion, even if they were treated with insulin for decades. Early screening and genetic testing are important to improve the prognosis of patients with neonatal diabetes mellitus arising from ABCC8 or KCNJ11 mutation.